Mumps Drug Market By Product By Type (RIT 4385, Schwarz, Wistar RA 27/3, Others), By End-User (Hospital, Clinic), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2024-2033
-
46915
-
May 2024
-
300
-
-
This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Report Overview
The Mumps Drug Market was valued at USD 750.0 Million in 2023. It is expected to reach USD 1152.0 Million by 2033, with a CAGR of 4.5% during the forecast period from 2024 to 2033.
The Mumps Drug Market encompasses the development, production, and distribution of pharmaceuticals designed to prevent and treat mumps, an acute viral illness. This market includes vaccines, antiviral medications, and supportive treatments aimed at mitigating the disease's symptoms and complications. Key drivers include increasing vaccination initiatives, growing awareness about mumps prevention, and rising incidences of outbreaks due to vaccine hesitancy. Regulatory approvals, technological advancements in vaccine production, and strategic collaborations among pharmaceutical companies significantly influence market dynamics.
The Mumps Drug Market is poised for significant growth in the coming years, driven by a confluence of technological advancements, evolving regulatory landscapes, and increasing global healthcare awareness. Current market trends suggest a robust pipeline of novel therapeutics, underpinned by extensive R&D investments from leading pharmaceutical companies. The sector is witnessing a paradigm shift towards more efficient and patient-friendly treatments, spurred by innovations in biotechnology and precision medicine.
Furthermore, the integration of Environmental, Social, and Governance (ESG) criteria is increasingly becoming a critical factor for stakeholders, influencing both corporate strategies and investment decisions. This shift towards sustainability and ethical governance is expected to enhance the market’s credibility and attract more investors who are keen on sustainable health solutions.
The comprehensive report on the Mumps Drug Market includes a PESTEL analysis that underscores the macroeconomic factors shaping the industry. Political stability, economic growth, social trends, technological innovations, environmental regulations, and legal frameworks collectively contribute to the market dynamics. Technological trend analysis within the report highlights significant advancements such as the development of next-generation vaccines, enhanced drug delivery systems, and the adoption of AI and machine learning for drug discovery and development. These technological strides are pivotal in addressing the unmet needs in mumps treatment and prevention, thus expanding market opportunities.
Key Takeaways
- Market Growth: The Mumps Drug Market was valued at USD 750.0 Million in 2023. It is expected to reach USD 1152.0 Million by 2033, with a CAGR of 4.5% during the forecast period from 2024 to 2033.
- By Type: RIT 4385 leads the mumps drug market with strategic advantages.
- By End-User: Hospitals dominate the mumps drug market; clinics ensure early diagnosis access.
- Regional Dominance: North America leads the mumps drug market with a 40% share.
- Growth Opportunity: Advancements in vaccine technology and new therapies are driving substantial growth in the global mumps drug market.
Driving factors
Increasing Prevalence of Mumps: Fueling Demand for Effective Treatments
The escalating incidence of mumps globally is a primary driver for the growth of the mumps drug market. The World Health Organization (WHO) has reported a resurgence in mumps cases, particularly in regions with declining vaccination rates. This resurgence necessitates the development and distribution of effective antiviral treatments and vaccines. As mumps is a highly contagious viral infection, outbreaks can rapidly expand within populations, increasing the urgency and demand for pharmaceutical interventions. Pharmaceutical companies are investing in research and development (R&D) to create more effective treatments and vaccines, anticipating a rise in market demand. The increasing prevalence of mumps directly correlates with the necessity for improved and accessible medical solutions, driving market expansion.
Growing Awareness About Vaccines: Enhancing Prevention and Market Growth
Enhanced awareness and education about the importance of vaccinations have significantly impacted the mumps drug market. Public health campaigns and government initiatives have highlighted vaccines' critical role in preventing mumps outbreaks. For instance, the Centers for Disease Control and Prevention (CDC) has launched several initiatives aimed at increasing vaccination coverage among children and adults. This growing awareness has led to higher vaccination rates, which, while primarily preventive, also encourage the development of booster vaccines and treatments for those who contract the disease.
High Prevalence of Pneumococcal Infections: Indirectly Boosting the Mumps Drug Market
The high prevalence of pneumococcal infections, which often lead to complications in mumps patients, indirectly supports the growth of the mumps drug market. Patients with weakened immune systems or pre-existing conditions, such as pneumococcal infections, are more susceptible to severe mumps complications. This interplay necessitates a comprehensive treatment approach, often involving both antiviral drugs and antibiotics to manage secondary infections. The co-management of these conditions drives the demand for a broader range of pharmaceutical products.
Additionally, the overlap in vaccination strategies for pneumococcal infections and mumps (as part of broader immunization programs) enhances market dynamics. Increased investment in immunization programs for pneumococcal infections often includes components that address mumps, thereby expanding the market scope for mumps drugs and vaccines.
Restraining Factors
Waning Immunity: A Significant Challenge to Sustained Market Growth
Waning immunity among vaccinated individuals is a critical factor restraining the growth of the mumps drug market. Research indicates that the effectiveness of the mumps vaccine diminishes over time, with immunity potentially declining as early as a decade after the initial vaccination. This decrease in vaccine-induced immunity contributes to periodic outbreaks even in highly vaccinated populations, thereby necessitating additional booster doses to maintain community protection.
The need for repeated booster doses underscores a potential increase in market demand for mumps vaccines and related drugs. However, this also points to a persistent challenge: the continuous need to educate the public and healthcare providers about the importance of booster vaccinations.
Vaccine Contraindications: Limiting the Reach and Effectiveness of Vaccination Programs
Vaccine contraindications present a substantial barrier to the universal application of mumps vaccination programs, thereby affecting market growth. Contraindications such as severe allergic reactions to vaccine components, compromised immune systems, and certain pre-existing health conditions prevent some individuals from receiving the vaccine. This segment of the population remains vulnerable to mumps infections, potentially facilitating the spread of the virus even in communities with high vaccination coverage.
The presence of contraindications necessitates the development and availability of alternative prophylactic and therapeutic measures, including antiviral drugs and treatments tailored for individuals who cannot be vaccinated. Pharmaceutical companies must invest in R&D to address these gaps, which could lead to innovative solutions and drive market expansion.
By Type Analysis
RIT 4385 leads the mumps drug market with strategic advantages.
In 2023, RIT 4385 held a dominant market position in the "By Type" segment of the Mumps Drug Market. This segment is characterized by several key players, including RIT 4385, Schwarz, Wistar RA 27/3, and others. RIT 4385's leading position can be attributed to its robust clinical efficacy, widespread adoption in immunization programs, and strong safety profile, which have garnered the trust of healthcare providers and patients alike. Additionally, strategic partnerships and collaborations have enhanced its market penetration, contributing to its dominant status.
Schwarz, another significant player, has maintained a solid market presence due to its innovative formulations and targeted marketing strategies, which have effectively addressed specific demographic needs. However, it faces challenges in scaling up production to meet increasing demand.
Wistar RA 27/3, known for its historic contribution to mumps vaccination, continues to be a critical component in the market. Its long-standing reputation and proven track record of effectiveness ensure its steady utilization, especially in regions with established healthcare infrastructure. The "Others" category encompasses a variety of emerging and regional players that are gradually gaining traction through localized strategies and niche market focus. These players often introduce competitive pricing and innovative delivery methods to carve out their market share.
By End-User Analysis
Hospitals dominate the mumps drug market; clinics ensure early diagnosis access.
In 2023, Hospitals held a dominant market position in the end-user segment of the Mumps Drug Market. Hospitals, as critical healthcare infrastructure, have comprehensive facilities and specialist expertise necessary for diagnosing and treating mumps cases, contributing significantly to the high demand for mumps drugs. Their ability to handle severe complications associated with mumps, such as meningitis and encephalitis, underscores their pivotal role in the market. Additionally, hospitals often serve as primary centers for vaccination programs, further driving the uptake of mumps medications and prophylactics.
Conversely, clinics also play a crucial role in the mumps drug market. Clinics, typically more accessible and affordable than hospitals, provide essential services for the early diagnosis and treatment of mumps. They cater to a broad demographic, including those in rural and underserved urban areas, thereby enhancing market penetration. Clinics often act as first contact points for patients with mumps, facilitating early intervention and management. Their contribution to public health through routine immunization and outpatient care makes them indispensable in the overall strategy to control and treat mumps, complementing the more intensive care provided by hospitals.
Key Market Segments
By Type
- RIT 4385
- Schwarz
- Wistar RA 27/3
- Others
By End-User
- Hospital
- Clinic
Growth Opportunity
Advancements in Vaccine Technology
The global mumps drug market is poised for substantial growth in 2024, driven significantly by advancements in vaccine technology. Innovations in vaccine delivery systems and formulations have markedly improved the efficacy and accessibility of mumps vaccines. The development of next-generation vaccines, which offer broader protection and longer-lasting immunity, is particularly noteworthy. Enhanced cold chain logistics and the rise of needle-free delivery methods are also expanding reach, especially in developing regions where mumps outbreaks remain a public health challenge. These technological strides not only bolster vaccination rates but also stimulate demand for related pharmaceutical products, creating a robust growth trajectory for the market.
Development of New Therapies
In parallel with vaccine advancements, the development of new therapies for mumps presents another critical growth opportunity. Recent research has focused on antiviral drugs that can mitigate the severity of mumps symptoms and prevent complications, such as orchitis and meningitis, which can result from the infection. These therapeutic innovations are especially vital given the resurgence of mumps cases in various regions, often linked to vaccine hesitancy and waning immunity among older populations.
The introduction of novel antiviral medications, coupled with comprehensive treatment protocols, is expected to significantly reduce the disease burden and enhance patient outcomes. Consequently, pharmaceutical companies investing in mumps-specific therapies are well-positioned to capture emerging market opportunities.
Latest Trends
Advancements in Technology: Revolutionizing Mumps Treatment and Vaccine Development
Technological advancements will be at the forefront of the mumps drug market in 2024. Innovations in biotechnology and genomics are leading to the development of more effective vaccines and therapeutic solutions. Cutting-edge mRNA technology, which proved successful with COVID-19 vaccines, is being explored for its potential in mumps prevention. This technology offers the possibility of creating vaccines with higher efficacy rates and faster production timelines.
Additionally, advancements in diagnostic tools are improving early detection and management of mumps, which is crucial in controlling outbreaks. Enhanced data analytics and AI-driven research are also accelerating drug discovery and development processes, reducing time-to-market for new treatments.
Collaborations and Partnerships: Strategic Alliances Driving Market Expansion and Innovation
Collaborations and partnerships are increasingly critical in the mumps drug market. Pharmaceutical companies are joining forces with biotechnology firms, research institutions, and governments to leverage complementary strengths and resources. These strategic alliances are essential for advancing research, sharing knowledge, and reducing development costs. For instance, joint ventures and licensing agreements are facilitating the rapid development and distribution of new vaccines.
Moreover, public-private partnerships are playing a pivotal role in funding large-scale clinical trials and ensuring equitable access to treatments, particularly in low- and middle-income countries. These collaborations are not only fostering innovation but also enhancing the global capacity to respond to mumps outbreaks efficiently.
Regional Analysis
North America leads the mumps drug market with a 40% share.
The global mumps drug market exhibits distinct regional trends and dynamics, with significant variations in market size, growth potential, and healthcare infrastructure. North America stands out as the dominant region, commanding approximately 40% of the global market share. This dominance is attributable to advanced healthcare facilities, high vaccination coverage, and substantial investment in healthcare research and development. The U.S. and Canada are key contributors, driven by strong governmental support and high awareness about mumps prevention and treatment.
In Europe, the mumps drug market is bolstered by well-established healthcare systems and comprehensive immunization programs. Countries such as the UK, Germany, and France lead the market, with increasing emphasis on immunization and public health initiatives.
The Asia Pacific region is poised for significant growth, fueled by rising healthcare expenditure, expanding population, and increasing awareness about infectious diseases. Countries like China, India, and Japan are key players, with substantial investments in healthcare infrastructure and vaccination programs.
The Middle East & Africa region presents a mixed scenario, with variable healthcare standards and access to medical facilities. However, increasing government initiatives to improve healthcare access and vaccination coverage are expected to drive market growth. Latin America exhibits moderate growth potential, with countries like Brazil and Mexico at the forefront. These nations are focusing on enhancing healthcare infrastructure and immunization efforts to combat mumps outbreaks effectively.
Key Regions and Countries
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Netherlands
- Russia
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- Singapore
- Thailand
- South Korea
- Vietnam
- India
- New Zealand
- Rest of Asia Pacific
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- The rest of the Middle East & Africa
Key Players Analysis
The global Mumps Drug Market in 2024 is characterized by significant contributions from several key players, each leveraging unique strengths to drive growth and innovation.
Beijing Minhai Biotechnology Co. Ltd and Beijing Tiantan Biological Products Co. Ltd. stand out in the Chinese market due to their extensive R&D capabilities and strong government support. Their focus on developing cost-effective mumps vaccines positions them as crucial players in addressing public health needs within and beyond China. China National Pharmaceutical Group Corporation, another Chinese giant, leverages its vast distribution network and robust financial resources to enhance vaccine accessibility. Its strategic partnerships and investments in biotech innovations underscore its pivotal role in the market.
GlaxoSmithKline Plc (GSK), a global leader in pharmaceuticals, brings unparalleled expertise in vaccine development. GSK's established global presence and commitment to advanced research ensure its continued influence and capability to set industry standards in mumps vaccine efficacy and safety. Organic Vaccines and Prometheon Pharma represent the innovative edge of the market, focusing on novel delivery mechanisms and vaccine formulations. Their advancements in organic and needle-free vaccines could revolutionize the market by improving compliance and expanding reach.
Sinovac Biotech Ltd., with its proven track record in vaccine production and rapid response to epidemics, remains a critical player. Sinovac's agile manufacturing processes and strong regulatory compliance enhance its competitive advantage. Zydus Cadila Healthcare Limited, an Indian pharmaceutical leader, combines affordable healthcare solutions with robust research initiatives. Its focus on expanding vaccine accessibility in developing regions aligns with global public health goals.
Market Key Players
- Beijing Minhai Biotechnology Co. Ltd
- Beijing Tiantan Biological Products Co. Ltd.
- China National Pharmaceutical Group Corporation
- GlaxoSmithKline Plc
- Organic Vaccines
- Prometheon Pharma
- Sinovac Biotech Ltd.
- Zydus Cadila Healthcare Limited
Recent Development
- In May 2024, According to Market Research Reports, the mumps drug market is projected to grow significantly, driven by increasing vaccination initiatives and rising awareness about mumps prevention. Key players such as GlaxoSmithKline and Beijing Tiantan Biological Products Co., Ltd. are expanding their production capabilities to meet this growing demand.
- In April 2024, Fierce Pharma listed a new mumps vaccine among the top 10 most anticipated drug launches of the year. This launch by Sinovac Biotech Ltd. aims to address the rising demand for effective mumps immunization, particularly in regions with lower vaccination rates.
- In March 2024, the World Health Organization (WHO) published an updated position paper on mumps vaccines, emphasizing the importance of the Measles, Mumps, and Rubella (MMR) vaccine in controlling outbreaks globally. The report highlighted changes in the epidemiological features of mumps and underscored the need for increased vaccination coverage to prevent the spread of the virus.
Report Scope
Report Features Description Market Value (2023) USD 750.0 Million Forecast Revenue (2033) USD 1152.0 Million CAGR (2024-2032) 4.5% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Type (RIT 4385, Schwarz, Wistar RA 27/3, Others), By End-User (Hospital, Clinic) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Beijing Minhai Biotechnology Co. Ltd, Beijing Tiantan Biological Products Co. Ltd., China National Pharmaceutical Group Corporation, GlaxoSmithKline Plc, Organic Vaccines, Prometheon Pharma, Sinovac Biotech Ltd., Zydus Cadila Healthcare Limited Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Mumps Drug Market Overview
- 2.1. Mumps Drug Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Mumps Drug Market Dynamics
- 3. Global Mumps Drug Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Mumps Drug Market Analysis, 2016-2021
- 3.2. Global Mumps Drug Market Opportunity and Forecast, 2023-2032
- 3.3. Global Mumps Drug Market Analysis, Opportunity and Forecast, By Type, 2016-2032
- 3.3.1. Global Mumps Drug Market Analysis by Type: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
- 3.3.3. RIT 4385
- 3.3.4. Schwarz
- 3.3.5. Wistar RA 27/3
- 3.3.6. Others
- 3.4. Global Mumps Drug Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
- 3.4.1. Global Mumps Drug Market Analysis by End-User: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
- 3.4.3. Hospital
- 3.4.4. Clinic
- 4. North America Mumps Drug Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Mumps Drug Market Analysis, 2016-2021
- 4.2. North America Mumps Drug Market Opportunity and Forecast, 2023-2032
- 4.3. North America Mumps Drug Market Analysis, Opportunity and Forecast, By Type, 2016-2032
- 4.3.1. North America Mumps Drug Market Analysis by Type: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
- 4.3.3. RIT 4385
- 4.3.4. Schwarz
- 4.3.5. Wistar RA 27/3
- 4.3.6. Others
- 4.4. North America Mumps Drug Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
- 4.4.1. North America Mumps Drug Market Analysis by End-User: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
- 4.4.3. Hospital
- 4.4.4. Clinic
- 4.5. North America Mumps Drug Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.5.1. North America Mumps Drug Market Analysis by Country : Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.5.2.1. The US
- 4.5.2.2. Canada
- 4.5.2.3. Mexico
- 5. Western Europe Mumps Drug Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Mumps Drug Market Analysis, 2016-2021
- 5.2. Western Europe Mumps Drug Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Mumps Drug Market Analysis, Opportunity and Forecast, By Type, 2016-2032
- 5.3.1. Western Europe Mumps Drug Market Analysis by Type: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
- 5.3.3. RIT 4385
- 5.3.4. Schwarz
- 5.3.5. Wistar RA 27/3
- 5.3.6. Others
- 5.4. Western Europe Mumps Drug Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
- 5.4.1. Western Europe Mumps Drug Market Analysis by End-User: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
- 5.4.3. Hospital
- 5.4.4. Clinic
- 5.5. Western Europe Mumps Drug Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.5.1. Western Europe Mumps Drug Market Analysis by Country : Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.5.2.1. Germany
- 5.5.2.2. France
- 5.5.2.3. The UK
- 5.5.2.4. Spain
- 5.5.2.5. Italy
- 5.5.2.6. Portugal
- 5.5.2.7. Ireland
- 5.5.2.8. Austria
- 5.5.2.9. Switzerland
- 5.5.2.10. Benelux
- 5.5.2.11. Nordic
- 5.5.2.12. Rest of Western Europe
- 6. Eastern Europe Mumps Drug Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Mumps Drug Market Analysis, 2016-2021
- 6.2. Eastern Europe Mumps Drug Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Mumps Drug Market Analysis, Opportunity and Forecast, By Type, 2016-2032
- 6.3.1. Eastern Europe Mumps Drug Market Analysis by Type: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
- 6.3.3. RIT 4385
- 6.3.4. Schwarz
- 6.3.5. Wistar RA 27/3
- 6.3.6. Others
- 6.4. Eastern Europe Mumps Drug Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
- 6.4.1. Eastern Europe Mumps Drug Market Analysis by End-User: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
- 6.4.3. Hospital
- 6.4.4. Clinic
- 6.5. Eastern Europe Mumps Drug Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.5.1. Eastern Europe Mumps Drug Market Analysis by Country : Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.5.2.1. Russia
- 6.5.2.2. Poland
- 6.5.2.3. The Czech Republic
- 6.5.2.4. Greece
- 6.5.2.5. Rest of Eastern Europe
- 7. APAC Mumps Drug Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Mumps Drug Market Analysis, 2016-2021
- 7.2. APAC Mumps Drug Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Mumps Drug Market Analysis, Opportunity and Forecast, By Type, 2016-2032
- 7.3.1. APAC Mumps Drug Market Analysis by Type: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
- 7.3.3. RIT 4385
- 7.3.4. Schwarz
- 7.3.5. Wistar RA 27/3
- 7.3.6. Others
- 7.4. APAC Mumps Drug Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
- 7.4.1. APAC Mumps Drug Market Analysis by End-User: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
- 7.4.3. Hospital
- 7.4.4. Clinic
- 7.5. APAC Mumps Drug Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.5.1. APAC Mumps Drug Market Analysis by Country : Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.5.2.1. China
- 7.5.2.2. Japan
- 7.5.2.3. South Korea
- 7.5.2.4. India
- 7.5.2.5. Australia & New Zeland
- 7.5.2.6. Indonesia
- 7.5.2.7. Malaysia
- 7.5.2.8. Philippines
- 7.5.2.9. Singapore
- 7.5.2.10. Thailand
- 7.5.2.11. Vietnam
- 7.5.2.12. Rest of APAC
- 8. Latin America Mumps Drug Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Mumps Drug Market Analysis, 2016-2021
- 8.2. Latin America Mumps Drug Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Mumps Drug Market Analysis, Opportunity and Forecast, By Type, 2016-2032
- 8.3.1. Latin America Mumps Drug Market Analysis by Type: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
- 8.3.3. RIT 4385
- 8.3.4. Schwarz
- 8.3.5. Wistar RA 27/3
- 8.3.6. Others
- 8.4. Latin America Mumps Drug Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
- 8.4.1. Latin America Mumps Drug Market Analysis by End-User: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
- 8.4.3. Hospital
- 8.4.4. Clinic
- 8.5. Latin America Mumps Drug Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.5.1. Latin America Mumps Drug Market Analysis by Country : Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.5.2.1. Brazil
- 8.5.2.2. Colombia
- 8.5.2.3. Chile
- 8.5.2.4. Argentina
- 8.5.2.5. Costa Rica
- 8.5.2.6. Rest of Latin America
- 9. Middle East & Africa Mumps Drug Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Mumps Drug Market Analysis, 2016-2021
- 9.2. Middle East & Africa Mumps Drug Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Mumps Drug Market Analysis, Opportunity and Forecast, By Type, 2016-2032
- 9.3.1. Middle East & Africa Mumps Drug Market Analysis by Type: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
- 9.3.3. RIT 4385
- 9.3.4. Schwarz
- 9.3.5. Wistar RA 27/3
- 9.3.6. Others
- 9.4. Middle East & Africa Mumps Drug Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
- 9.4.1. Middle East & Africa Mumps Drug Market Analysis by End-User: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
- 9.4.3. Hospital
- 9.4.4. Clinic
- 9.5. Middle East & Africa Mumps Drug Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.5.1. Middle East & Africa Mumps Drug Market Analysis by Country : Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.5.2.1. Algeria
- 9.5.2.2. Egypt
- 9.5.2.3. Israel
- 9.5.2.4. Kuwait
- 9.5.2.5. Nigeria
- 9.5.2.6. Saudi Arabia
- 9.5.2.7. South Africa
- 9.5.2.8. Turkey
- 9.5.2.9. The UAE
- 9.5.2.10. Rest of MEA
- 10. Global Mumps Drug Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Mumps Drug Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Mumps Drug Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. Beijing Minhai Biotechnology Co. Ltd
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. Beijing Tiantan Biological Products Co. Ltd.
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. China National Pharmaceutical Group Corporation
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. GlaxoSmithKline Plc
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. Organic Vaccines
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. Prometheon Pharma
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. Sinovac Biotech Ltd.
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Zydus Cadila Healthcare Limited
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.13.1. Company Overview
- 11.13.2. Financial Highlights
- 11.13.3. Product Portfolio
- 11.13.4. SWOT Analysis
- 11.13.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
"
- List of Figures
- "
- Figure 1: Global Mumps Drug Market Revenue (US$ Mn) Market Share by Type in 2022
- Figure 2: Global Mumps Drug Market Market Attractiveness Analysis by Type, 2016-2032
- Figure 3: Global Mumps Drug Market Revenue (US$ Mn) Market Share by End-Userin 2022
- Figure 4: Global Mumps Drug Market Market Attractiveness Analysis by End-User, 2016-2032
- Figure 5: Global Mumps Drug Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 6: Global Mumps Drug Market Market Attractiveness Analysis by Region, 2016-2032
- Figure 7: Global Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Figure 8: Global Mumps Drug Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 9: Global Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Figure 10: Global Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Figure 11: Global Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 12: Global Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Figure 13: Global Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Figure 14: Global Mumps Drug Market Market Share Comparison by Region (2016-2032)
- Figure 15: Global Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Figure 16: Global Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Figure 17: North America Mumps Drug Market Revenue (US$ Mn) Market Share by Typein 2022
- Figure 18: North America Mumps Drug Market Market Attractiveness Analysis by Type, 2016-2032
- Figure 19: North America Mumps Drug Market Revenue (US$ Mn) Market Share by End-Userin 2022
- Figure 20: North America Mumps Drug Market Market Attractiveness Analysis by End-User, 2016-2032
- Figure 21: North America Mumps Drug Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 22: North America Mumps Drug Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 23: North America Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Figure 24: North America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 25: North America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Figure 26: North America Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Figure 27: North America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 28: North America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Figure 29: North America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Figure 30: North America Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Figure 31: North America Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Figure 32: North America Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Figure 33: Western Europe Mumps Drug Market Revenue (US$ Mn) Market Share by Typein 2022
- Figure 34: Western Europe Mumps Drug Market Market Attractiveness Analysis by Type, 2016-2032
- Figure 35: Western Europe Mumps Drug Market Revenue (US$ Mn) Market Share by End-Userin 2022
- Figure 36: Western Europe Mumps Drug Market Market Attractiveness Analysis by End-User, 2016-2032
- Figure 37: Western Europe Mumps Drug Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 38: Western Europe Mumps Drug Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 39: Western Europe Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Figure 40: Western Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 41: Western Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Figure 42: Western Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Figure 43: Western Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 44: Western Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Figure 45: Western Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Figure 46: Western Europe Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Figure 47: Western Europe Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Figure 48: Western Europe Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Figure 49: Eastern Europe Mumps Drug Market Revenue (US$ Mn) Market Share by Typein 2022
- Figure 50: Eastern Europe Mumps Drug Market Market Attractiveness Analysis by Type, 2016-2032
- Figure 51: Eastern Europe Mumps Drug Market Revenue (US$ Mn) Market Share by End-Userin 2022
- Figure 52: Eastern Europe Mumps Drug Market Market Attractiveness Analysis by End-User, 2016-2032
- Figure 53: Eastern Europe Mumps Drug Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 54: Eastern Europe Mumps Drug Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 55: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Figure 56: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 57: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Figure 58: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Figure 59: Eastern Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 60: Eastern Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Figure 61: Eastern Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Figure 62: Eastern Europe Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Figure 63: Eastern Europe Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Figure 64: Eastern Europe Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Figure 65: APAC Mumps Drug Market Revenue (US$ Mn) Market Share by Typein 2022
- Figure 66: APAC Mumps Drug Market Market Attractiveness Analysis by Type, 2016-2032
- Figure 67: APAC Mumps Drug Market Revenue (US$ Mn) Market Share by End-Userin 2022
- Figure 68: APAC Mumps Drug Market Market Attractiveness Analysis by End-User, 2016-2032
- Figure 69: APAC Mumps Drug Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 70: APAC Mumps Drug Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 71: APAC Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Figure 72: APAC Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 73: APAC Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Figure 74: APAC Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Figure 75: APAC Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 76: APAC Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Figure 77: APAC Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Figure 78: APAC Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Figure 79: APAC Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Figure 80: APAC Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Figure 81: Latin America Mumps Drug Market Revenue (US$ Mn) Market Share by Typein 2022
- Figure 82: Latin America Mumps Drug Market Market Attractiveness Analysis by Type, 2016-2032
- Figure 83: Latin America Mumps Drug Market Revenue (US$ Mn) Market Share by End-Userin 2022
- Figure 84: Latin America Mumps Drug Market Market Attractiveness Analysis by End-User, 2016-2032
- Figure 85: Latin America Mumps Drug Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 86: Latin America Mumps Drug Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 87: Latin America Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Figure 88: Latin America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 89: Latin America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Figure 90: Latin America Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Figure 91: Latin America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 92: Latin America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Figure 93: Latin America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Figure 94: Latin America Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Figure 95: Latin America Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Figure 96: Latin America Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Figure 97: Middle East & Africa Mumps Drug Market Revenue (US$ Mn) Market Share by Typein 2022
- Figure 98: Middle East & Africa Mumps Drug Market Market Attractiveness Analysis by Type, 2016-2032
- Figure 99: Middle East & Africa Mumps Drug Market Revenue (US$ Mn) Market Share by End-Userin 2022
- Figure 100: Middle East & Africa Mumps Drug Market Market Attractiveness Analysis by End-User, 2016-2032
- Figure 101: Middle East & Africa Mumps Drug Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 102: Middle East & Africa Mumps Drug Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 103: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Figure 104: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 105: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Figure 106: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Figure 107: Middle East & Africa Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 108: Middle East & Africa Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Figure 109: Middle East & Africa Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Figure 110: Middle East & Africa Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Figure 111: Middle East & Africa Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Figure 112: Middle East & Africa Mumps Drug Market Market Share Comparison by End-User (2016-2032)
"
- List of Tables
- "
- Table 1: Global Mumps Drug Market Market Comparison by Type (2016-2032)
- Table 2: Global Mumps Drug Market Market Comparison by End-User (2016-2032)
- Table 3: Global Mumps Drug Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 4: Global Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Table 5: Global Mumps Drug Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 6: Global Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Table 7: Global Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Table 8: Global Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 9: Global Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Table 10: Global Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Table 11: Global Mumps Drug Market Market Share Comparison by Region (2016-2032)
- Table 12: Global Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Table 13: Global Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Table 14: North America Mumps Drug Market Market Comparison by End-User (2016-2032)
- Table 15: North America Mumps Drug Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 16: North America Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Table 17: North America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 18: North America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Table 19: North America Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Table 20: North America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 21: North America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Table 22: North America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Table 23: North America Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Table 24: North America Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Table 25: North America Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Table 26: Western Europe Mumps Drug Market Market Comparison by Type (2016-2032)
- Table 27: Western Europe Mumps Drug Market Market Comparison by End-User (2016-2032)
- Table 28: Western Europe Mumps Drug Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 29: Western Europe Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Table 30: Western Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 31: Western Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Table 32: Western Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Table 33: Western Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 34: Western Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Table 35: Western Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Table 36: Western Europe Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Table 37: Western Europe Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Table 38: Western Europe Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Table 39: Eastern Europe Mumps Drug Market Market Comparison by Type (2016-2032)
- Table 40: Eastern Europe Mumps Drug Market Market Comparison by End-User (2016-2032)
- Table 41: Eastern Europe Mumps Drug Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 42: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Table 43: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 44: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Table 45: Eastern Europe Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Table 46: Eastern Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 47: Eastern Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Table 48: Eastern Europe Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Table 49: Eastern Europe Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Table 50: Eastern Europe Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Table 51: Eastern Europe Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Table 52: APAC Mumps Drug Market Market Comparison by Type (2016-2032)
- Table 53: APAC Mumps Drug Market Market Comparison by End-User (2016-2032)
- Table 54: APAC Mumps Drug Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: APAC Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Table 56: APAC Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: APAC Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Table 58: APAC Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Table 59: APAC Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 60: APAC Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Table 61: APAC Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Table 62: APAC Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Table 63: APAC Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Table 64: APAC Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Table 65: Latin America Mumps Drug Market Market Comparison by Type (2016-2032)
- Table 66: Latin America Mumps Drug Market Market Comparison by End-User (2016-2032)
- Table 67: Latin America Mumps Drug Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 68: Latin America Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Table 69: Latin America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 70: Latin America Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Table 71: Latin America Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Table 72: Latin America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 73: Latin America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Table 74: Latin America Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Table 75: Latin America Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Table 76: Latin America Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Table 77: Latin America Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- Table 78: Middle East & Africa Mumps Drug Market Market Comparison by Type (2016-2032)
- Table 79: Middle East & Africa Mumps Drug Market Market Comparison by End-User (2016-2032)
- Table 80: Middle East & Africa Mumps Drug Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 81: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) (2016-2032)
- Table 82: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 83: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) Comparison by Type (2016-2032)
- Table 84: Middle East & Africa Mumps Drug Market Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
- Table 85: Middle East & Africa Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 86: Middle East & Africa Mumps Drug Market Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
- Table 87: Middle East & Africa Mumps Drug Market Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
- Table 88: Middle East & Africa Mumps Drug Market Market Share Comparison by Country (2016-2032)
- Table 89: Middle East & Africa Mumps Drug Market Market Share Comparison by Type (2016-2032)
- Table 90: Middle East & Africa Mumps Drug Market Market Share Comparison by End-User (2016-2032)
- 1. Executive Summary
-
- Beijing Minhai Biotechnology Co. Ltd
- Beijing Tiantan Biological Products Co. Ltd.
- China National Pharmaceutical Group Corporation
- GlaxoSmithKline Plc
- Organic Vaccines
- Prometheon Pharma
- Sinovac Biotech Ltd.
- Zydus Cadila Healthcare Limited
Our Clients
View Our Licence Options
